Flag of the European Union EU Clinical Trials Register Help

Clinical trials for multiple sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: multiple sclerosis. Displaying page 27 of 32.
    «« First « Previous 23  24  25  26  27  28  29  30  31  Next» Last»»
    EudraCT Number: 2009-016442-74 Sponsor Protocol Number: CMM-EM Start Date*: Information not available in EudraCT
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo.
    Medical condition: Esclerosis Múltiple
    Disease: Version SOC Term Classification Code Term Level
    9 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002545-10 Sponsor Protocol Number: OSU6162Open1309 Start Date*: 2014-01-08
    Sponsor Name:A. Carlsson Research AB
    Full Title: An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g P...
    Medical condition: Parkinsons disease Huntingtons disease Multiple scleros Brain trauma Stroke Myalgic encephalomyelitis Narcolepsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002204-33 Sponsor Protocol Number: C32322 Start Date*: 2007-03-02
    Sponsor Name:UCB Pharma S.A.
    Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose...
    Medical condition: Relapsing forms of multiple slerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004451-40 Sponsor Protocol Number: H15/02 Start Date*: 2016-02-17
    Sponsor Name:Almirall Hermal GmbH
    Full Title: SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL
    Medical condition: Moderate to severe spasticity due to MS (multiple sclerosis).
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003471-30 Sponsor Protocol Number: D-FR-52120-222 Start Date*: 2016-09-26
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) PT (Completed) CZ (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004255-38 Sponsor Protocol Number: cnp-MS-0601/MC-2006-01 Start Date*: 2007-01-05
    Sponsor Name:Bionorica research GmbH
    Full Title: Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated wit...
    Medical condition: Patients with multiple sclerosis associated with central neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DK (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004014-41 Sponsor Protocol Number: BA1106006 Start Date*: 2006-12-28
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776A in patients...
    Medical condition: Mild Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012748-17 Sponsor Protocol Number: ELN115727-301 Start Date*: 2010-03-11
    Sponsor Name:Janssen Alzheimer Immunotherapy
    Full Title: A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's di...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000207-36 Sponsor Protocol Number: 275AS101 Start Date*: 2020-11-18
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 ...
    Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10052653 Amyotrophic lateral sclerosis gene carrier PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010661-23 Sponsor Protocol Number: 2009-010661-23 Start Date*: 2009-07-30
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition: subjects affected by secondary-progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005113-39 Sponsor Protocol Number: SSP-2 Start Date*: 2013-04-08
    Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis
    Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002728-33 Sponsor Protocol Number: CUPID2005 Start Date*: 2006-02-28
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Cannabinoid Use in Progressive Inflammatory brain Disease
    Medical condition: Progressive multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000381-20 Sponsor Protocol Number: 27820 Start Date*: 2007-11-16
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-004519-43 Sponsor Protocol Number: NN18344 Start Date*: 2005-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001960-31 Sponsor Protocol Number: 142/2019 Start Date*: 2019-08-27
    Sponsor Name:Turku PET centre
    Full Title: Effect of cladribine treatment on microglial activation in the CNS
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003622-16 Sponsor Protocol Number: T214/2016 Start Date*: 2017-09-19
    Sponsor Name:Turku University Hospital
    Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000073-64 Sponsor Protocol Number: 003 Start Date*: 2004-09-03
    Sponsor Name:Merck & Co., Inc./Suomen MSD Oy
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by...
    Medical condition: Aaltomainen MS-tauti
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-001356-22 Sponsor Protocol Number: CLR_09_21 Start Date*: 2016-07-13
    Sponsor Name:Sun Pharma Advanced Research Company Ltd.
    Full Title: A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THE EFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS
    Medical condition: Spasticity due to multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000639-15 Sponsor Protocol Number: TG1101-RMS302 Start Date*: 2017-12-04
    Sponsor Name:TG Therapeutics
    Full Title: Phase III: UbliTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10029202 Nervous system disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005752-38 Sponsor Protocol Number: CBAF312ADE03 Start Date*: 2021-03-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC)
    Medical condition: secondary progressive multiple sclerosis (SPMS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 23  24  25  26  27  28  29  30  31  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 14:51:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA